

LIST OF FIGURES AND TABLES

CHAPTER-1

Figure 3. 3: Age dependent effect of a single dose of cadmium at GSH and LPO level	5
Figure 3. 2: Age dependent effect of a single dose of cadmium on rat prostate	52
Figure 3. 1: Time dependent effect of a single dose of cadmium	51
CHAPTER-3	
Table 1. 3: Molecular alterations in BPH and PCa	28
Table 1. 2: Different models to study BPH pathogenesis: Benefits and drawbacks	21
Table 1. 1: Composition and significance of Prostatic fluid	6
Figure 1. 17: Shared risk factors between BPH and PCa	27
Figure 1. 16: Comparative histology	27
Figure 1. 15: Epithelial- stromal interaction in the prostate	18
Figure 1. 14: Benign prostate hyperplasia	13
Figure 1. 13: Pathological conditions of prostate	13
Figure 1. 12: Prostatic disorders	12
Figure 1. 11: ER signalling in cell	10
Figure 1. 10: AR signaling in cell	10
Figure 1. 9: AR Gene Structure	9
Figure 1. 8: Conversion of testosterone into dihydrotestosterone (DHT)(DHT)	8
Figure 1. 7: Steroid hormone action through specific receptors during prostatic development	7
Figure 1. 6: semen volume portion distribution	<i>6</i>
Figure 1. 5: Age dependant Testosterone level in human	5
Figure 1. 4: Prenatal to postnatal morphology and development of prostate	4
Figure 1. 3: Prostate gland cells organization and their identity markers	
Figure 1. 2: histology of normal prostate gland	2
Figure 1. 1: Prostatic Zones	2

Figure 3. 4: Age dependent histological changes of a single dose of cadmium	54
Figure 3. 5: Histological evaluation	55
Figure 3. 6: Effect of a single dose of cadmium on castrated rat prostate	55
Figure 3. 7: Effect of a single dose of cadmium along with steroid hormone receptor antagonist on prostate weight and prostatic acid phosphatase activity	.56
Figure 3. 8: Histological changes in rat prostate of a single dose of cadmium treated group along wit antagonistst	
Figure 3. 9: Effect of a single dose of cadmium on prostatic genes expression profile in presence of antagonists	.57
Figure 3. 10: Effect of a single dose of cadmium on expression profile of ki-67 and AR on rat prostate in the presence of antagonists by immunofluorescence	
Figure 3. 11: Effect of a single dose of cadmium on expression profile of vimentin and e-cadherin on prostate in the presence of antagonists by immunofluorescence	
Table 3. 1: Histological analysis of Cd treated rat prostate gland	49
Table 3. 2: Reverse Transcriptase-PCR Primers Sequence and Annealing temperature	50
CHAPTER-4(A)	
Figure 4(A). 1: Isolation and characterization of isolated prostate cells from BPH patient	.78
Figure 4(A). 2: Characterization of isolated prostate cells.	.79
Figure 4(A). 3: FACS analysis of cell surface markers of isolated prostate cells	.81
Figure 4(A). 4: Isolated prostate cells express pluripotent stem cell markers	.82
Figure 4(A). 5: Ectodermal cell lineages differintiatioj of prostate cells.	.83
Figure 4(A). 6: Oil O red staining of isolated prostate cells after culture	.83
Figure 4(I). 7: Alizrain red S staining of isolated prostate cells after culture	.84
Figure 4(I). 8: Alcian blue staining of isolated prostate cells after culture.	.85
Figure 4(A). 9: Endodermal cell lineages differentiation of isolated prostate cells	.85
Figure 4(A). 10: Teratoma formation in vivo.	86
Table 4(A). 1: Primer Sequence and annealing temperature	74

CHAPTER-4(B)

Figure 4(B). 1: Determination of Cd cytotoxic concentrations	99
Figure 4(B). 2: Growth curve.	100
Figure 4(B). 3: Morphological analysis	101
Figure 4(B). 4: Cell cycle analysis	102
Figure 4(B). 5: Gene expression profile	103
Figure 4(B). 6: Desitometric analysis of Gene expression profile	104
Figure 4(B). 7: Protein expression	105
Figure 4(B). 8: Densitometric analysis of protein expression	105
Figure 4(B). 9: FACS analysis of p63 protein expression level in cells	106
Figure 4(B). 10: Immunocytochemistry of AR and ER-α	107
Figure 4(II). 11: Immunocytochemistry of ki-67	108
Figure 4(B). 12: Wound healing assay	109
Figure 4(B). 13: Zone of clearance in Gelatin Zymography gel for MMPs	110
Figure 4(B). 14: Densitometry fo Zymography gel	110
Table 4(B). 1: Primer Sequence and annealing temperature	96
Table 4(B). 2: Doubling time of Cadmium treated and MNU treated cells	99
CHAPTER-5	
Figure 5. 1: PCR amplification and restriction digestion patterns gelgel	123
Figure 5. 2: Genotype correlation of smokers v/s non-smokers in control and patients	128
Figure 5. 3: Gene expression of AR, PSA, 5α Reductase and ERβ	129
Figure 5. 4: Genotype Phenotype correlation of AR, PSA, ER eta and 5 $lpha$ Reductase genes	130
Figure 5. 5: Protein profile of AR and p63 genes	130
Figure 5. 6: Correlation of AR and p63 protein expression with AR genotype	131
Table 5. 1: Polymorphisms studied in the study	
Table 5. 2: Gene specific Primers sequence for SNP study	122

To Understand The Etiopathogenesis of Benign Prostate Hyperplasia at Biochemical, Cellular and Molecular level.

Ph.D Thesis, 2014, MESCRL, MSU

Table 5. 3: PCR conditions for prostate genes	. 122
Table 5. 4: Restriction endonucleases and their recognition sites	. 123
Table 5. 5: Association studies for the androgen receptor (AR) gene A/G polymorphism	. 125
Table 5. 6: Association studies for the Prostate Specific Antigen (PSA) gene A/G polymorphism	. 126
Table 5. 7: Association studies for the Estrogen Receptor- β (ER- β) gene A/G polymorphism	. 126
Table 5. 8: Distribution of AR, PSA and ERβ Genotypes	. 126

ANNEXURE-I

PROSTATE DISORDERS – QUESTIONNAIRE



Department of Biochemistry
Faculty of Science
The M.S University of Baroda
Vadodara- 390002

DATE: INVIGILATOR:	SERIAL CODE:
PERSONAL DETAILS: Name:	
Phone: Native: Diet: Vegetarian/ Non-vegetarian/ Omnitarian Additive Habits: Tobacco/ Smoking/ Alcohol/ Oth Occupation: Q- Are you exposed to a pollutant(s) at your work If yes, nature of pollutant: Land/ Water/ Air/ Other	ers: place or at your place of residence? Yes/No
HISTORY OF ANY MAJOR ILLNESS: Q- Are you suffering from any lifestyle disorder(s) If yes, nature of disorders: Diabetes/ Obesity/ Cho Cardiac disorder/ other: Symptoms associated: Duration of disorder:	9? Yes/No lesterol disorder/
Q- What made you suspect that you have a prostat	ic disorder?
Q- Anyone in your family ever detected with a pro- If yes, first / second / third degree relative. Relation	

Ph.D Thesis, 2014, MESCRL, MSU

PROSTATIC DISORDER(S):	
Diagnosis (tick):	
[] PSA screening (if yes, leve	l: ng/ml blood/ serum)
[] Digital rectal examination	(DRE)
[] Trans rectal ultrasound (TI	RUS)
[] Prostate needle biopsy	
[] Others:	
Suspected Prostatic Disorder (t	ick):
[] Prostatitis (if yes, State: ac	·
	ia (if yes, state: mild / moderate / severe)
	te: Benign/ Metastatic
	Neoplasia (PIN) Grade: I / II / III
	1/2/3/4/5, Gleason score:+_=)
Any other associated symptom	·
If yes, symptoms	
Treatment (tick):	
	es, which:)
Any other drug (if yes nat	re:, which:)
[] Transurethral resection of	
Laser removal of the disea	•
[] Complete removal of the v	•
Post treatment recovery: excell	
	nptoms (if any):
General comment:	nptonis (ii aliy).
	T TO OF THE CAMPIE
POST EXAMINATION RESU	
Protein level:	
	_ μ moles PNP formed/min/l tissue
SOD activity:	enzyme required for 50% inhibition Pyrogallol autoxidation
Catalase activity:	mmoles of H ₂ O ₂ decomposed/ min/g Tissue
	_nmoles of MDA formed / mg Protein
	$\Delta \log (GSH) / \min / mg \text{ protein}$
GSH level:	
Vitamin E:	
Vitamin C:	
Cd level:	μg/ g tissue
Zn level:	μg/ g tissue
Pd level:	μg/ g tissue
_	
I,	have understood the aim of this study and willing
to donate 3 ml blood sample for	r this purpose.
Patient's signature	Date: